Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2025C508 Product name: Combinatie van epinephrine en dodecylmaltoside, in alle vormen beschermd door het basisoctrooi

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2025C/508
Type:
Certificate
SPC type:
Medical
Basic patent number:
197518079
Status:
Open & Published
Publication number:
2025C508
1rst applicant's nationality:
Procedural language:
Dutch

Marketing authorization

Marketing authorization number:
EU/1/24/1846
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
23/08/2024
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
18/02/2025
First marketing authorization date:
23/08/2024
Grant date:
Activation date:
BE Publication date:
03/03/2025
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
23/08/2039
SPC/SPC Extension Expiration (if granted and all annual fees paid):
Rejection date:
Withdrawal date:

Applicant

1

Name:
ARS Pharmaceuticals Operations, Inc.
Legal Form:
Inc.
From:
18/02/2025
Address:
11682 El Camino Real, Suite 120, San Diego, California 92130, United States (US)
To:

2

Name:
Aegis Therapeutics, LLC
Legal Form:
LLC
From:
18/02/2025
Address:
3430 Carmel Mountain Road, Suite 300, San Diego CA 92121, United States (US)
To:

Agent

Name:
GEVERS PATENTS
Legal Form:
From:
19/02/2025
Address:
De Kleetlaan 7A, 1831, DIEGEM, Belgium (BE)
To:

Publication

Bulletin

Bulletin heading:
SPC
Journal edition number:
2025/05
Publication date:
05/06/2025
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates
Filing date Document type Publication Type Document Description Number of pages File Type
05/03/2025 Outgoing Correspondence 2 PDF /9/2/0/2/1/0722512029/docs/2025c508_0_outgoingcorrespondence_20250305_034720397.pdf
18/02/2025 Application Form 4 PDF /9/2/0/2/1/0722512029/docs/2025c508_1_applicationform_20250219_084600455.pdf
18/02/2025 MA Official Publication Official Publication of 1st Marketing Authorization 11 PDF /9/2/0/2/1/0722512029/docs/2025c508_2_maofficialpublication_20250219_084559854.pdf
18/02/2025 General Document Other 3 PDF /9/2/0/2/1/0722512029/docs/2025c508_3_generaldocument_20250219_084559043.pdf
18/02/2025 General Document Other 15 PDF /9/2/0/2/1/0722512029/docs/2025c508_4_generaldocument_20250219_084558935.pdf
18/02/2025 General Document Other 165 PDF /9/2/0/2/1/0722512029/docs/2025c508_5_generaldocument_20250219_084556419.pdf
18/02/2025 General Document Other 5 PDF /9/2/0/2/1/0722512029/docs/2025c508_6_generaldocument_20250219_084558843.pdf
18/02/2025 Marketing Authorization 1st Paediatric Marketing Authorization (EU) 1 PDF /9/2/0/2/1/0722512029/docs/2025c508_7_marketingauthorization_20250219_084559115.pdf
18/02/2025 Abstract Product Characteristics Abstract of the characteristics of the product 38 PDF /9/2/0/2/1/0722512029/docs/2025c508_8_abstractproductcharacteristics_20250219_084559426.pdf
18/02/2025 Marketing Authorization 1st Marketing Authorization (EU) 3 PDF /9/2/0/2/1/0722512029/docs/2025c508_9_marketingauthorization_20250219_084600188.pdf
18/02/2025 General Document Other 1 PDF /9/2/0/2/1/0722512029/docs/2025c508_10_generaldocument_20250219_084556305.pdf
18/02/2025 General Document Other 14 PDF /9/2/0/2/1/0722512029/docs/2025c508_11_generaldocument_20250219_084607647.pdf
18/02/2025 Incoming Correspondence (Email) Cover letter 1 PDF /9/2/0/2/1/0722512029/docs/2025c508_12_incomingcorrespondenceelectronic_20250219_084607388.pdf
03/03/2025 Publication I1 1 PDF /9/2/0/2/1/0722512029/docs/2025c508_13_i1document_20250303_172403312.pdf